Tokyo Tape
Sign in
← OncoTherapy Science

Quarterly report · Q1

4564.TEDINET S100OW16
Period2022-04-01 → 2022-06-30
Filed2022-08-08
StandardJapan GAAP
ConsolidatedYes
Data checks10 of 10 passed
Key figures · 30
MetricValuePeriodScopeSource row
Revenue¥386m2022-04-01 → 2022-06-30Cons.Net sales
Revenue¥93m2021-04-01 → 2021-06-30Cons.Net sales
Operating income−¥307m2022-04-01 → 2022-06-30Cons.Operating income
Operating income−¥572m2021-04-01 → 2021-06-30Cons.Operating income
Ordinary income−¥314m2022-04-01 → 2022-06-30Cons.Ordinary income
Ordinary income−¥2.1bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥572m2021-04-01 → 2021-06-30Cons.Ordinary income
Profit before tax−¥277m2022-04-01 → 2022-06-30Cons.Income before income taxes
Profit before tax−¥535m2021-04-01 → 2021-06-30Cons.Income before income taxes
Net income (owners)−¥278m2022-04-01 → 2022-06-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥2.6bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥535m2021-04-01 → 2021-06-30Cons.Profit loss attributable to owners of parent
Net income−¥278m2022-04-01 → 2022-06-30Cons.Profit loss
Net income−¥535m2021-04-01 → 2021-06-30Cons.Profit loss
Total assets¥2.0bnat 2022-06-30Cons.Assets
Total assets¥2.7bnat 2022-03-31Cons.Assets
Total assets¥3.6bnat 2021-06-30Cons.Total assets (5-year summary)
Total liabilities¥373mat 2022-06-30Cons.Liabilities
Total liabilities¥705mat 2022-03-31Cons.Liabilities
Net assets / equity¥1.7bnat 2022-06-30Cons.Net assets
Net assets / equity¥2.0bnat 2022-03-31Cons.Net assets
Net assets / equity¥3.2bnat 2021-06-30Cons.Net assets (5-year summary)
Cash and deposits¥1.5bnat 2022-06-30Cons.Cash and deposits
Cash and deposits¥1.8bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥-1.442022-04-01 → 2022-06-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-13.722021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-32021-04-01 → 2021-06-30Cons.Basic earnings loss per share (5-year summary)
Equity ratio79.3%at 2022-06-30Cons.Equity to asset ratio (5-year summary)
Equity ratio70.6%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio87.6%at 2021-06-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 29
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-06-30−¥55,000
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-06-30−¥55,000
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-06-30−¥101m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2022-04-01 → 2022-06-30¥380m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2022-04-01 → 2022-06-30¥380m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2022-04-01 → 2022-06-30¥9m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2022-04-01 → 2022-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2022-04-01 → 2022-06-30¥55,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2022-04-01 → 2022-06-30−¥215m
—segment totalrevenue2022-04-01 → 2022-06-30¥386m
—segment totalrevenue external2022-04-01 → 2022-06-30¥386m
—segment totalrevenue intersegment2022-04-01 → 2022-06-30¥55,000
—segment totalsegment profit2022-04-01 → 2022-06-30−¥206m
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-06-30−¥8m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-06-30−¥8m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-06-30−¥107m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue2021-04-01 → 2021-06-30¥96m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue external2021-04-01 → 2021-06-30¥87m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥8m
jpcrp040300-q1r_E05363-000Cancer Precision Medical Businessreportable segmentsegment profit2021-04-01 → 2021-06-30−¥33m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue2021-04-01 → 2021-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue external2021-04-01 → 2021-06-30¥6m
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentrevenue intersegment2021-04-01 → 2021-06-30¥62,000
jpcrp040300-q1r_E05363-000Research And Development Of Pharmaceutical Productsreportable segmentsegment profit2021-04-01 → 2021-06-30−¥431m
—segment totalrevenue2021-04-01 → 2021-06-30¥102m
—segment totalrevenue external2021-04-01 → 2021-06-30¥93m
—segment totalrevenue intersegment2021-04-01 → 2021-06-30¥8m
—segment totalsegment profit2021-04-01 → 2021-06-30−¥464m

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 313
ItemContextValueUnit
Foreign exchange losses noePrior1YTDDuration307000JPY
Foreign exchange losses noeCurrentYTDDuration6740000JPY
Non operating expensesPrior1YTDDuration444000JPY
Non operating expensesCurrentYTDDuration6740000JPY
Ordinary incomePrior1YTDDuration-571509000JPY
Ordinary incomeCurrentYTDDuration-314093000JPY
Gain on sales of noncurrent assets eiPrior1YTDDuration49000JPY
Gain on sales of noncurrent assets eiCurrentYTDDuration－JPY
Gain on reversal of subscription rights to shares eiPrior1YTDDuration47853000JPY
Gain on reversal of subscription rights to shares eiCurrentYTDDuration37755000JPY
Extraordinary incomePrior1YTDDuration47902000JPY
Extraordinary incomeCurrentYTDDuration37755000JPY
Impairment loss elPrior1YTDDuration11036000JPY
Impairment loss elCurrentYTDDuration751000JPY
Extraordinary lossPrior1YTDDuration11036000JPY
Extraordinary lossCurrentYTDDuration751000JPY
Income before income taxesPrior1YTDDuration-534644000JPY
Income before income taxesCurrentYTDDuration-277089000JPY
Income taxes currentPrior1YTDDuration724000JPY
Income taxes currentCurrentYTDDuration724000JPY
Income taxes deferredPrior1YTDDuration-439000JPY
Income taxes deferredCurrentYTDDuration-14000JPY
Income taxesPrior1YTDDuration284000JPY
Income taxesCurrentYTDDuration710000JPY
Profit lossPrior1YTDDuration-534929000JPY
Profit lossCurrentYTDDuration-277799000JPY
Profit loss attributable to owners of parentPrior1YTDDuration-534929000JPY
Profit loss attributable to owners of parentCurrentYTDDuration-277799000JPY
Profit lossPrior1YTDDuration-534929000JPY
Profit lossCurrentYTDDuration-277799000JPY
Comprehensive incomePrior1YTDDuration-534929000JPY
Comprehensive incomeCurrentYTDDuration-277799000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration-534929000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration-277799000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember5875000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember87307000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember93183000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration93183000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember62000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember8333000JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember8395000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-8395000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember5938000JPY
Net salesPrior1YTDDuration_jpcrp040300-q1r_E05363-000CancerPrecisionMedicalBusinessReportableSegmentsMember95640000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember101579000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-8395000JPY
Net salesPrior1YTDDuration93183000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q1r_E05363-000ResearchAndDevelopmentOfPharmaceuticalProductsReportableSegmentsMember-431256000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 10 of 10 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-06-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-06-30pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-06-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-06-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-06-30pass